Table 1.
Neutralization by the indicated anti-V3 mAbs and GP vaccine sera against subtype B viruses with and without sCD4 present
| sCD4 IC80 ug/ml | 447-52D 10 ug/ml | 2219 10 ug/ml | 3074 10 ug/ml | 82-2 1:10 | 82-4 1:10 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| −sCD4 | +sCD4 | −sCD4 | +sCD4 | −sCD4 | +sCD4 | −sCD4 | +sCD4 | −sCD4 | +sCD4 | ||
| JRFL | 7.2 | 36% | 99% | 32% | 98% | 0% | 94% | 29% | 100% | 31% | 97% |
| ADA | 1.7 | 72% | 82% | 62% | 78% | 63% | 69% | 55% | 73% | 58% | 67% |
| YU2 | 1.4 | 2% | 73% | 0% | 64% | 25% | 41% | 9% | 97% | 29% | 40% |
| 6535.3 | 8.6 | 87% | 93% | 93% | 93% | 24% | 74% | 17% | 85% | 4% | 16% |
| QH0692.42 | 6.4 | 27% | 51% | 28% | 45% | 68% | 73% | 46% | 66% | 12% | 47% |
| SC422661.8 | 125.3 | 0% | 16% | 18% | 25% | 18% | 18% | 41% | 0% | 37% | 22% |
| PVO.4 | 46.0 | 4% | 43% | 35% | 63% | 39% | 57% | 56% | 90% | 44% | 71% |
| TRO.11 | >200 | 50% | 48% | 31% | 37% | 29% | 13% | 70% | 75% | 66% | 67% |
| AC10.0.29 | 80.9 | 8% | 39% | 47% | 57% | 13% | 12% | 59% | 80% | 13% | 55% |
| RHPA4259.7 | 21.6 | 36% | 34% | 29% | 37% | 34% | 45% | 15% | 12% | 9% | 11% |
| THRO4156.18 | 3.1 | 25% | 0% | 14% | 12% | 10% | 8% | 38% | 39% | 23% | 21% |
| REJO4541.67 | 22.5 | 31% | 21% | 47% | 74% | 29% | 55% | 34% | 78% | 6% | 41% |
| TRJO4551.58 | 17.7 | 0% | 86% | 0% | 83% | 5% | 65% | 0% | 87% | 14% | 73% |
| WITO4160.33 | 50.0 | 40% | 76% | 15% | 67% | 12% | 41% | 31% | 68% | 34% | 55% |
| CAAN5342.A2 | 95.2 | 30% | 26% | 39% | 26% | 32% | 17% | 46% | 67% | 34% | 59% |
| Breadth | 2(13%) | 7(47%) | 2(13%) | 9(60%) | 2(13%) | 7(47%) | 4(27%) | 12(80%) | 2(13%) | 8(53%) | |
| P-value | 0.0625 | 0.016 | 0.0625 | 0.008 | 0.031 | ||||||
Values indicate percent neutralization when no sCD4 was present in the assay (−sCD4) and with sCD4 present (+sCD4) at a concentration sufficient to inhibit viral entry by 80%. The later value is the percent adjusted neutralization and indicates the effect of the mAb or GP sera calculated based on baseline viral entry with sCD4 present. The second column shows the concentration of sCD4 required to inhibit viral entry by 80%. Note that the IC80 for sCD4 was derived separately for each virus and the percent adjusted neutralization mediated by mAb or GP sera was calculated using viral entry values at this level of sCD4 (e.g., Fig. 3). Values greater than 50% neutralization are shown in bold and were used to calculate the breadth of neutralization. P-values were computed using the two-sided McNemar’s test.